Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics, Inc. (former Nasdaq: SAGE) is a Cambridge, Massachusetts-based biopharmaceutical company focused on brain health, with a particular emphasis on postpartum depression. The company reports that it developed the only two FDA-approved treatments indicated for postpartum depression and highlights ZURZUVAE (zuranolone), described as the first-and-only oral treatment for adults with postpartum depression and, in some communications, as a once-daily 14-day oral treatment.
The news flow around Sage has centered on several themes. One major area is commercial updates for ZURZUVAE, including collaboration revenue recognized under its agreement with Biogen, prescription shipment trends for women with postpartum depression, prescriber behavior among obstetrician-gynecologists, and payer coverage metrics. Regular quarterly earnings releases have discussed revenue from ZURZUVAE, other collaboration revenue, research and development spending, selling, general and administrative expenses, restructuring charges, and cash runway expectations.
Another recurring topic is Sage’s research and development pipeline. Company news has described progress with SAGE-319, an extrasynaptic-preferring GABAA receptor positive allosteric modulator being studied for behavioral symptoms associated with certain neurodevelopmental disorders, along with preclinical NMDA receptor negative allosteric modulator programs SAGE-817 and SAGE-039, and evaluation of potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies.
Corporate and strategic developments are also prominent in Sage’s news. Releases have covered a strategic alternatives review, unsolicited acquisition proposals, and, ultimately, the definitive agreement and subsequent completion of an acquisition by Supernus Pharmaceuticals, Inc. Investors reviewing SAGE-related news can use this page to follow historical earnings announcements, pipeline updates, leadership changes, strategic reviews, and the steps that led to Sage becoming a wholly owned subsidiary of Supernus.
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company dedicated to developing innovative therapies for brain disorders, will present at two key investor conferences in November 2020. The events include a fireside chat at the Stifel Virtual Healthcare Conference on November 16 at 8:40 am ET and a presentation at the Wolfe Research Virtual Healthcare Conference on November 19 at 4:05 pm ET. Investors can access live webcasts on Sage's investor page, with replays available for 30 days post-event.
Sage Therapeutics (NASDAQ: SAGE) announces that CEO Jeff Jonas, M.D. will undergo a scheduled surgical procedure today. The company expects him to make a full recovery and return to his role by December 2020. During his recovery, the Sage leadership team will oversee business operations, with support from the Board of Directors. Sage Therapeutics is focused on developing innovative therapies for brain disorders, aiming to improve brain health through its neurology, depression, and neuropsychiatry programs.
Sage Therapeutics announced a live webcast on November 5, 2020, at 8:30 a.m. ET to present its third quarter 2020 financial results and discuss recent business updates. The event will be accessible via the investor page on Sage's website. A replay of the webcast will be available shortly after the event and will remain archived for 30 days. Sage Therapeutics focuses on developing innovative therapies for brain disorders, aiming to enhance brain health through its depression and neurology programs.
Sage Therapeutics reported interim results from the Phase 3 SHORELINE Study evaluating zuranolone for major depressive disorder (MDD). The study indicated that zuranolone 30 mg was generally well-tolerated, with 71.6% of patients achieving a response after treatment. Approximately 70% of participants required only one or two treatment courses. Notably, 447 patients (61.7%) experienced adverse events, mostly mild or moderate. The study aims to provide insights into zuranolone's use as an as-needed treatment for MDD. Comprehensive results are expected in 2021.
Sage Therapeutics, Inc. (NASDAQ: SAGE) has appointed Barry Greene to its Board of Directors. Greene's extensive experience includes serving as President of Alnylam Pharmaceuticals and leading successful oncology strategies at Millennium Pharmaceuticals. His appointment aligns with Sage's commitment to innovation in brain health treatments. CEO Jeff Jonas emphasized Greene's leadership and operational excellence as vital to advancing the company's programs in depression and neurology. Greene expressed excitement about contributing to Sage’s mission of providing novel treatment options for central nervous system disorders.